Dr. Reddy's Laboratories zooms on entering into trade generics business in India
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Dr. Reddy's Laboratories is currently trading at Rs. 5007.45, up by 107.75 points or 2.20% from its previous closing of Rs. 4899.70 on the BSE.
The scrip opened at Rs. 4901.35 and has touched a high and low of Rs. 5015.00 and Rs. 4901.35 respectively. So far 50358 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 5021.15 on 19-Jun-2023 and a 52 week low of Rs. 3996.10 on 19-Sep-2022.
Last one week high and low of the scrip stood at Rs. 5021.15 and Rs. 4864.25 respectively. The current market cap of the company is Rs. 83292.74 crore.
The promoters holding in the company stood at 26.70%, while Institutions and Non-Institutions held 50.30% and 11.70% respectively.
Dr. Reddy's Laboratories has entered into the trade generics business in India with the launch of its new dedicated division ‘RGenX’. Through this, Dr. Reddy’s aims to provide patients with access to a wider range of products and increased affordability. The new business will further the company’s goal of reaching over 1.5 billion patients by 2030.
Dr. Reddy’s aims to roll out its trade generics across cities and towns in India, including rural areas. The company will work closely with its channel partners to ensure availability of its products.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
